Charana Perera*, Tony Bragg, Melanie Rich, Trevor Hollingsworth

Department of Psychiatry, Pine Rivers Private Hospital, Brisbane, Australia

*Corresponding Author: Charana Perera, Department of Psychiatry, Pine Rivers Private Hospital, Brisbane, Australia.

Received: April 04, 2022; Published: May 24, 2022

Abstract

Drug-induced Parkinsonism (DIP) is a common intersection for Neurologists and Psychiatrists. Here we present a patient with a high probability of Drug-induced Parkinsonism (DIP) with striatal hand deformity as a sign of DIP. The case is extremely rare and may provide clues to the condition's overlapping nature and pathogenesis, particularly given her prolonged exposure to early generation dopamine antagonists. Furthermore, we have not identified a reported case of striatal hand contractures in a patient with drug-induced Parkinsonism, which sheds light on essential clinical and ethical conundrums.

Keywords: Drug-Induced Parkinsonism; Striatal Deformity; iPD

1. Charcot J. “Lectures on the Diseases of the Nervous System”. The New Sydenham Society: London. British and Foreign Medico-Chirurgical Review.119 (1877): 180-181.
2. Gortvai P. “Deformities of the hands and feet in Parkinsonism and their reversibility by operation”. Journal of Neurology, Neurosurgery and Psychiatry 26 (1963): 33-36.
3. Martin J. “The Basal Ganglia, and Posture”. London Pitman Medical (1967): 100-117.
4. Raghuvanshi A., et al. “Striatal Toe”. Journal of the Association of Physicians of India 12 (2015): 68.
5. Bovi T., et al. “The status of olfactory function and the striatal dopaminergic system in drug-induced Parkinsonism”. Journal of Neurology 257.11 (2010): 1882-1889.
6. Lee PH., et al. “Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug-induced Parkinsonism”. Journal of Neurology, Neurosurgery and Psychiatry 11 (2007): 1250-1252.
7. Morley JF., et al. “Motor and non-motor features of Parkinson's disease that predict persistent druginduced Parkinsonism”. Parkinsonism and Related Disorders 20 (7 (2014): 738-742.
8. Hassin-Baer S., et al. “Clinical characteristics of neuroleptic-induced Parkinsonism”. Journal of Neural Transmission (Vienna)11 (2001): 1299-1308.
9. Sethi KD and EY Zamrini. “Asymmetry in clinical features of drug-induced Parkinsonism”. The Journal of Neuropsychiatry and Clinical Neurosciences 1 (1990): 64-66.
10. Hoyles K and JC Sharma. “Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach”. Journal of Neurology 12 (2013): 2951-2958.
11. Alvarez MV and VG Evidence. “Understanding drug-induced parkinsonism: separating pearls from oysters”. Neurology8 (2008): e32-34.
12. Tinazzi M., et al. “Clinical and [123I] FP-CIT SPET imaging follow-up in patients with druginduced Parkinsonism”. Journal of Neurology 6 (2009): 910-915.
13. Cummings JL., et al. “The role of dopaminergic Imaging in patients with symptoms of dopaminergic system neurodegeneration”. BrainPt 11 (2011): 3146-3166.
14. Lee SH., et al. “Clinical Features Indicating Nigrostriatal Dopaminergic Degeneration in DrugInduced Parkinsonism”. Journal of Movement Disorders 1 (2017): 35-39.
15. Sung YH., et al. “Drug-induced Parkinsonism versus Idiopathic Parkinson Disease: Utility of Nigrosome 1 with 3-T Imaging”. Radiology3 (2016): 849-858.
16. Ashour R and J Jankovic. “Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy”. Movement Disorders 11 (2006): 1856-1863.
17. Ashour R., et al. “Striatal deformities of the hand and foot in Parkinson's disease”. Lancet Neurology7 (2005): 423-431.

Citation

Citation: Charana Perera and Trevor Hollingsworth. “Between the Devil and the Deep Blue Sea: A Rare Case of Striatal Deformity in Drug-Induced Parkinsonism Charana Perera". Acta Scientific Neurology 5.6 (2022): 41-45.

Copyright

Copyright: © 2022 Charana Perera and Trevor Hollingsworth. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.